CO2018011554A2 - Formulaciones de nanopartículas lipídicas para componentes de cas/crispr - Google Patents

Formulaciones de nanopartículas lipídicas para componentes de cas/crispr

Info

Publication number
CO2018011554A2
CO2018011554A2 CONC2018/0011554A CO2018011554A CO2018011554A2 CO 2018011554 A2 CO2018011554 A2 CO 2018011554A2 CO 2018011554 A CO2018011554 A CO 2018011554A CO 2018011554 A2 CO2018011554 A2 CO 2018011554A2
Authority
CO
Colombia
Prior art keywords
crispr
lipid nanoparticles
formulations components
nanoparticles formulations
cas
Prior art date
Application number
CONC2018/0011554A
Other languages
English (en)
Inventor
David V Morrissey
Mihir Chandrakant Patel
Jonathan D Finn
Amy Madison Rhoden Smith
Lucinda J Shaw
Christian Dombrowski
Ruchi Rudraprasad Shah
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201662315602P priority Critical
Priority to US201662375776P priority
Priority to US201662433228P priority
Priority to US201762468300P priority
Priority to PCT/US2017/024973 priority patent/WO2017173054A1/en
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of CO2018011554A2 publication Critical patent/CO2018011554A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Abstract

La invención proporciona composiciones a base de nanopartículas y métodos útiles para administrar componentes de edición genética de CRISPR/Cas.
CONC2018/0011554A 2016-03-30 2018-10-26 Formulaciones de nanopartículas lipídicas para componentes de cas/crispr CO2018011554A2 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US201662315602P true 2016-03-30 2016-03-30
US201662375776P true 2016-08-16 2016-08-16
US201662433228P true 2016-12-12 2016-12-12
US201762468300P true 2017-03-07 2017-03-07
PCT/US2017/024973 WO2017173054A1 (en) 2016-03-30 2017-03-30 Lipid nanoparticle formulations for crispr/cas components

Publications (1)

Publication Number Publication Date
CO2018011554A2 true CO2018011554A2 (es) 2019-02-08

Family

ID=58632585

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011554A CO2018011554A2 (es) 2016-03-30 2018-10-26 Formulaciones de nanopartículas lipídicas para componentes de cas/crispr

Country Status (11)

Country Link
US (1) US20190136231A1 (es)
EP (1) EP3436077A1 (es)
JP (1) JP2019516351A (es)
KR (1) KR20190002493A (es)
CN (1) CN109475646A (es)
AU (1) AU2017244143A1 (es)
BR (1) BR112018069795A2 (es)
CA (1) CA3018978A1 (es)
CO (1) CO2018011554A2 (es)
TW (1) TW201802242A (es)
WO (1) WO2017173054A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
TW201825679A (zh) * 2016-12-08 2018-07-16 美商英特利亞醫療公司 經修飾之嚮導rna
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3641834A1 (en) 2017-06-19 2020-04-29 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
EP3585160A2 (en) 2017-07-31 2020-01-01 Regeneron Pharmaceuticals, Inc. Crispr reporter non-human animals and uses thereof
CN110891419A (zh) 2017-07-31 2020-03-17 瑞泽恩制药公司 评价crispr/cas-诱导的与外源供体核酸的体内重组
SG11201912235PA (en) 2017-07-31 2020-01-30 Regeneron Pharma Cas-transgenic mouse embryonic stem cells and mice and uses thereof
KR20200058509A (ko) * 2017-09-29 2020-05-27 인텔리아 테라퓨틱스, 인크. Attr 아밀로이드증의 ttr 유전자 편집 및 치료를 위한 조성물 및 방법
TW201924724A (zh) * 2017-09-29 2019-07-01 美商英特利亞醫療公司 調配物
EP3585162A1 (en) 2017-09-29 2020-01-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus and methods of use
EP3688173A1 (en) 2017-09-29 2020-08-05 Intellia Therapeutics, Inc. In vitro method of mrna delivery using lipid nanoparticles
WO2019084025A1 (en) * 2017-10-23 2019-05-02 Montrose Biosystems Llc Single- and mixed-metal nanoparticles, nanoparticle conjugates, devices for making nanoparticles, and related methods of use
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
WO2019222277A1 (en) 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
WO2019226925A1 (en) 2018-05-24 2019-11-28 Translate Bio, Inc. Thioester cationic lipids
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
WO2019232208A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
US20200016274A1 (en) 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof
WO2019232095A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Vitamin cationic lipids
WO2019237069A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
WO2019246544A2 (en) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
US20200022921A1 (en) 2018-07-23 2020-01-23 Translate Bio, Inc. Dry powder formulations for messenger rna
WO2020028327A1 (en) 2018-07-31 2020-02-06 Intellia Therapeutics, Inc. Compositions and methods for hydroxyacid oxidase 1 ( hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
US20200085745A1 (en) 2018-08-29 2020-03-19 Translate Bio, Inc. Process of preparing mrna-loaded lipid nanoparticles
WO2020056294A1 (en) 2018-09-14 2020-03-19 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
WO2020069296A1 (en) 2018-09-28 2020-04-02 Intellia Therapeutics, Inc. Compositions and methods for lactate dehydrogenase (ldha) gene editing
WO2020081613A1 (en) 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
US20200268906A1 (en) 2018-10-18 2020-08-27 Intellia Therapeutics, Inc. Nucleic acid constructs and methods of use
US20200270617A1 (en) 2018-10-18 2020-08-27 Intellia Therapeutics, Inc. Compositions and methods for transgene expression from an albumin locus
US20200270618A1 (en) 2018-10-18 2020-08-27 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
WO2020082046A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
WO2020081933A1 (en) 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
WO2020097379A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Peg lipidoid compounds
WO2020097376A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
WO2020097511A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
WO2020097384A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
WO2020102172A2 (en) 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
WO2020106903A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
WO2020118041A1 (en) * 2018-12-05 2020-06-11 Intellia Therapeutics, Inc. Modified amine lipids
US20200196581A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020146344A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN110157778A (zh) * 2019-05-30 2019-08-23 浙江大学 一种用于核酸扩增产物防污染检测的crispr试剂体系的储存方法及检测管

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA2751342C (en) * 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
AU2010245933B2 (en) * 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
US8691750B2 (en) * 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
JP6738728B2 (ja) * 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
EA030650B1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10125092B2 (en) * 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Also Published As

Publication number Publication date
BR112018069795A2 (pt) 2019-01-29
US20190136231A1 (en) 2019-05-09
AU2017244143A1 (en) 2018-10-11
JP2019516351A (ja) 2019-06-20
CN109475646A (zh) 2019-03-15
WO2017173054A1 (en) 2017-10-05
TW201802242A (zh) 2018-01-16
KR20190002493A (ko) 2019-01-08
EP3436077A1 (en) 2019-02-06
CA3018978A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
TR201811077T4 (tr) İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
TR201809838T4 (tr) İmmünomodülatörler olarak 1,2,4-oksadiazol türevleri.
CY1120588T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
PE20190207A1 (es) Composiciones que comprenden cepas bacterianas
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PE20151070A1 (es) Inhibidores de la tirosina - quinasa de bruton
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CY1119502T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
BR112018069795A2 (pt) formulações de nanopartículas lipídicas para componentes de crispr/cas
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
UA117364C2 (uk) Похідні аматоксину
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια